Ocular Therapeutix Sets Investor Day to Detail AXPAXLI NDA Plans and Retinal Disease Pipeline — Ocular Therapeutix, Inc.

Event summary

Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City, featuring presentations from senior leadership and key opinion leaders in retinal disease.
The event will focus on the NDA submission plan for AXPAXLI in wet AMD, updates on SOL-R, SOL-X trials, and the registrational diabetic retinopathy program.
Prominent retinal disease experts Dr. Arshad M. Khanani, Dr. Lejla Vajzovic, and Dr. Darius M. Moshfeghi will participate in roundtable discussions.
A live webcast of the presentation will be available, with a replay archived for at least 30 days post-event.

The big picture

Ocular Therapeutix's Investor Day comes at a pivotal time as it seeks to position AXPAXLI as a leading treatment for wet AMD and diabetic retinopathy. The event underscores the company's strategic focus on leveraging its ELUTYX technology to address significant unmet needs in retinal disease. The participation of prominent KOLs highlights the clinical and commercial potential of its pipeline, setting the stage for potential regulatory and market milestones.

What we're watching

Regulatory Strategy: The pace at which Ocular Therapeutix advances the NDA submission for AXPAXLI will determine its competitive positioning in the wet AMD market.
Pipeline Execution: Whether the updates on SOL-R, SOL-X trials, and the diabetic retinopathy program meet or exceed investor expectations will be critical.
Commercialization Readiness: How Ocular Therapeutix plans to commercialize AXPAXLI, if approved, will signal its ability to scale and compete with established players.